Stem cell factor is implicated in microenvironmental interactions and cellular dynamics of chronic lymphocytic leukemia.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 29 08 2019
pubmed: 28 4 2020
medline: 28 5 2021
entrez: 28 4 2020
Statut: epublish

Résumé

The inflammatory cytokine stem cell factor (SCF, ligand of c-kit receptor) has been implicated as a pro-oncogenic driver and an adverse prognosticator in several human cancers. Increased SCF levels have recently been reported in a small series of patients with chronic lymphocytic leukemia (CLL), however its precise role in CLL pathophysiology remains elusive. In this study, CLL cells were found to express predominantly the membrane isoform of SCF, which is known to elicit a more robust activation of the c-kit receptor. SCF was significantly overexpressed in CLL cells compared to healthy tonsillar B cells and it correlated with adverse prognostic biomarkers, shorter time-to-first treatment and shorter overall survival. Activation of immune receptors and long-term cell-cell interactions with the mesenchymal stroma led to an elevation of SCF primarily in CLL cases with an adverse prognosis. Contrariwise, suppression of oxidative stress and the BTK inhibitor ibrutinib lowered SCF levels. Interestingly, SCF significantly correlated with mitochondrial dynamics and hypoxia-inducible factor-1a which have previously been linked with clinical aggressiveness in CLL. SCF was able to elicit direct biological effects in CLL cells, affecting redox homeostasis and cell proliferation. Overall, the aberrantly expressed SCF in CLL cells emerges as a key response regulator to microenvironmental stimuli while correlating with poor prognosis. On these grounds, specific targeting of this inflammatory molecule could serve as a novel therapeutic approach in CLL.

Identifiants

pubmed: 32336682
pii: haematol.2019.236513
doi: 10.3324/haematol.2019.236513
pmc: PMC7927890
doi:

Substances chimiques

KITLG protein, human 0
Pyrazoles 0
Pyrimidines 0
Stem Cell Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

692-700

Références

Blood Adv. 2016 Nov 22;1(1):47-61
pubmed: 29296695
EMBO J. 2007 Feb 7;26(3):891-901
pubmed: 17255936
Oncotarget. 2015 Oct 6;6(30):29833-46
pubmed: 26284584
Angiogenesis. 2018 May;21(2):229-236
pubmed: 29330760
Biomedicines. 2018 Mar 08;6(1):
pubmed: 29518044
Cancer Lett. 2011 Apr 28;303(2):108-17
pubmed: 21320746
Science. 2008 Dec 19;322(5909):1861-5
pubmed: 19095944
Blood. 2014 Apr 24;123(17):2663-72
pubmed: 24553174
Am J Hematol. 2014 Jan;89(1):74-82
pubmed: 24030933
F1000Res. 2014 Jan 28;3:28
pubmed: 24715976
FASEB J. 2014 Oct;28(10):4441-56
pubmed: 25002122
Int J Oncol. 2006 Oct;29(4):851-9
pubmed: 16964380
Oncotarget. 2016 Jun 14;7(24):35946-35959
pubmed: 27191993
FASEB J. 2012 Sep;26(9):3738-53
pubmed: 22637532
Blood. 2009 May 28;113(22):5568-74
pubmed: 19336759
Haematologica. 2020 Apr;105(4):1042-1054
pubmed: 31289209
Leukemia. 2009 Apr;23(4):679-85
pubmed: 19158834
Int J Cancer. 2019 Jun 1;144(11):2695-2706
pubmed: 30447004
Am J Hum Genet. 2015 Nov 5;97(5):647-60
pubmed: 26522471
Blood. 2011 Nov 10;118(19):5201-10
pubmed: 21911837
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Physiol Rev. 2012 Oct;92(4):1619-49
pubmed: 23073628
Carcinogenesis. 2014 Oct;35(10):2283-90
pubmed: 25086759
Pathol Oncol Res. 2019 Apr;25(2):611-624
pubmed: 30402808
Clin Cancer Res. 2016 Apr 1;22(7):1572-82
pubmed: 26660519
Crit Rev Oncol Hematol. 2013 Dec;88(3):655-66
pubmed: 23941728
Mol Med Rep. 2015 Nov;12(5):7374-88
pubmed: 26458979
Blood. 2015 May 28;125(22):3432-6
pubmed: 25778534
Nat Commun. 2018 Nov 8;9(1):4685
pubmed: 30410062
J Immunol. 2014 Jun 15;192(12):5471-5475
pubmed: 24829419
Oncogene. 2019 Sep;38(38):6550-6565
pubmed: 31363162
Crit Rev Oncol Hematol. 2016 May;101:207-12
pubmed: 27033307
Haematologica. 2011 Mar;96(3):408-16
pubmed: 21134984
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
PLoS One. 2015 Mar 23;10(3):e0121338
pubmed: 25799412
Immunity. 2015 Mar 17;42(3):406-17
pubmed: 25786173
Nat Commun. 2018 May 3;9(1):1787
pubmed: 29725010
Blood. 2008 Jan 1;111(1):219-28
pubmed: 17885078
J Leukoc Biol. 2013 Jan;93(1):161-70
pubmed: 23136257
Blood. 2008 Aug 15;112(4):1269-79
pubmed: 18524989
Nat Cell Biol. 2012 Feb 19;14(3):276-86
pubmed: 22344033
Redox Biol. 2017 Aug;12:208-215
pubmed: 28259101
Haematologica. 2014 Jul;99(7):1138-48
pubmed: 24986876
Arch Biochem Biophys. 1992 Oct;298(1):150-8
pubmed: 1381905
Cell. 2016 Oct 6;167(2):457-470.e13
pubmed: 27667687
Leuk Lymphoma. 2013 Oct;54(10):2274-80
pubmed: 23418895
Breast Cancer Res. 2013 Apr 11;15(2):R32
pubmed: 23577751

Auteurs

George I Gavriilidis (GI)

Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece

Stavroula Ntoufa (S)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece

Nikos Papakonstantinou (N)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece

Konstantia Kotta (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece

Triantafyllia Koletsa (T)

Department of Pathology, Faculty of Medicine, Aristotle University, Thessaloniki, Greece

Elisavet Chartomatsidou (E)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece

Theodoros Moysiadis (T)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

Niki Stavroyianni (N)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

Achilles Anagnostopoulos (A)

Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece

Eleni Papadaki (E)

Department of Medicine, University of Crete, Heraklion, Greece

Asterios S Tsiftsoglou (AS)

Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece

Kostas Stamatopoulos (K)

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH